Login / Signup

Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.

Sho TanakaMasaru KushimotoTsukasa NishizawaMasahiro TakuboKazutaka MitsukeJin IkedaMidori FujishiroKatsuhiko OgawaIchiro TsujinoYutaka SuzukiMasanori Abe
Published in: Clinical diabetes and endocrinology (2020)
This is a case of isolated ACTH deficiency possibly due to hypophysitis in a patient with advanced lung cancer, in whom recent routine examinations had shown unremarkable results. We therefore conclude that isolated ACTH deficiency can suddenly arise during pembrolizumab monotherapy, albeit probably only rarely. Caution should be exercised to make sure that adrenal insufficiency is recognized immediately in order to achieve swift recovery by steroid replacement.
Keyphrases
  • squamous cell
  • replacement therapy
  • advanced non small cell lung cancer
  • clinical practice
  • clinical trial
  • open label
  • combination therapy